Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

CALGARY, Jan. 31 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has met the initial criteria to proceed to full enrolment in its U.S. Phase II trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung.

According to the trial protocol, to proceed to full enrolment of 52 patients, Oncolytics had to demonstrate that at least one patient in the first 38 patients treated experienced a complete or partial response, or stable disease for greater than six months. The third patient treated in the study was demonstrated to have stable disease by RECIST criteria for more than six months as measured by CT scan. A PET scan taken at the same time showed that any residual mass was metabolically inert.

A total of 12 patients have received REOLYSIN(R) treatment to date, with five remaining on study. All 12 patients have been treated at the Cancer Therapy and Research Center, University of Texas Health Science Center in San Antonio, Texas (CTRC at UTHSCSA).

"We are very pleased to proceed to the second stage of the REOLYSIN(R) study," said Dr. Monica Mita, Principal Investigator at CTRC at UTHSCSA. "This unique targeted compound has met our expectations so far in terms of both tolerability and efficacy endpoints and we feel it is very important to continue to offer this agent to our patients."

"While still early, these are very encouraging results," said Dr. Karl Mettinger, Chief Medical Officer of Oncolytics. "There are few treatment options for patients with bone or soft tissue cancers, and we are pleased that the trial participants appear to be benefiting from REOLYSIN(R) treatment."

Patients are expected to be enrolled at three additional sites, which include the Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx, New York, the University of Michigan Comprehensive Cancer Center
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  Moerae Matrix Inc. announced today the initiation ... MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 ... characterized by inflammation and fibrosis.  The study, conducted ... is a double-blind, two-way cross-over design lipopolysaccharide (LPS) ... of MMI-0100 when given via inhalation to healthy ...
(Date:7/28/2015)... PARK, N.C., July 28, 2015  United Therapeutics Corporation ... results for the second quarter ended June 30, 2015. ... as compared to the second quarter of 2014 ... Jeffs, Ph.D., United Therapeutics, President and Co-Chief Executive ... to an increase in the number of patients ...
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, 2015 /PRNewswire/ ... health care services and one of the largest ... that its parent company and sole stockholder, Capella ... Medical Properties Trust, Inc. ("MPT") (NYSE: MPW ... cash.  The transaction is expected to be finalized ...
(Date:7/27/2015)... ... July 27, 2015 , ... Brady ... a new video: 3 Ways to GHS Labels . This video provides ... Globally Harmonized System (GHS) by effectively labeling chemical containers. , “With the fourth ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Brady Releases “3 Roads to GHS Labels” Video 2
... is a source of knowledge, and the future is a source ... (1936-2002) Ernest Mueller , ... rich source of study material, much of it meticulously collected, characterized ... While the majority of,this material was originally collected and preserved with ...
... , , ... , ... , , ... fermentation,particularly when using an NBS fermentor. Provided in a,question and answer format, this article covers ...
... , ... , ... producing mg quantities of proteins, virus or,cell mass from anchorage-dependent or suspension ... FibraStage system is,inexpensive, simple to operate, and disposable. Typical,yields of ...
Cached Biology Technology:Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA) 2Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA) 3Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA) 4Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA) 5Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA) 6Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA) 7Fundamentals of Fermentation: Techniques For Benchtop Fermentors 2Fundamentals of Fermentation: Techniques For Benchtop Fermentors 3Fundamentals of Fermentation: Techniques For Benchtop Fermentors 4Fundamentals of Fermentation: Techniques For Benchtop Fermentors 5Fundamentals of Fermentation: Techniques For Benchtop Fermentors 6Fundamentals of Fermentation: Techniques For Benchtop Fermentors 7Fundamentals of Fermentation: Techniques For Benchtop Fermentors 8Fundamentals of Fermentation: Techniques For Benchtop Fermentors 9Fundamentals of Fermentation: Techniques For Benchtop Fermentors 10Fundamentals of Fermentation: Techniques For Benchtop Fermentors 11Fundamentals of Fermentation: Techniques For Benchtop Fermentors 12Fundamentals of Fermentation: Techniques For Benchtop Fermentors 13Fundamentals of Fermentation: Techniques For Benchtop Fermentors 14Fundamentals of Fermentation: Techniques For Benchtop Fermentors 15Fundamentals of Fermentation: Techniques For Benchtop Fermentors 16Fundamentals of Fermentation: Techniques For Benchtop Fermentors 17Fundamentals of Fermentation: Techniques For Benchtop Fermentors 18Fundamentals of Fermentation: Techniques For Benchtop Fermentors 19Inoculation, Growth & Harvesting in a New Easy-to-Use Disposable Cell Culture System 2Inoculation, Growth & Harvesting in a New Easy-to-Use Disposable Cell Culture System 3Inoculation, Growth & Harvesting in a New Easy-to-Use Disposable Cell Culture System 4Inoculation, Growth & Harvesting in a New Easy-to-Use Disposable Cell Culture System 5Inoculation, Growth & Harvesting in a New Easy-to-Use Disposable Cell Culture System 6Inoculation, Growth & Harvesting in a New Easy-to-Use Disposable Cell Culture System 7Inoculation, Growth & Harvesting in a New Easy-to-Use Disposable Cell Culture System 8
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/8/2015)... -- The consumer products industry for innovative tech ... such as wearables, smart wallets & other smart technology are ... continues to rapidly grow.  Biometrics & Wearable Device Companies in ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ... GPRO ) and Baidu Inc. (NASDAQ: BIDU ) ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... than 20 million people in the U.S., and many more ... of developing mesothelioma, a malignant cancer of the membranes that ... therapies. Moreover, asbestos exposure increases the risk of lung cancer ... to understand why asbestos causes cancer. The ...
... Netherlands believe they are on the verge of developing ... to detect accurately chromosomal abnormalities in the developing foetus. ... is through amniocentesis or chorionic villus sampling, both of ... a miscarriage. Dr Suzanna Frints, a clinical geneticist ...
... sunlight or water limit the size and photosynthetic capacity of a ... a tree? These are all questions that Alana Oldham of ... her colleagues dangled from an ancient redwood tree well over a ... Most trees, and many other plants, have thicker leaves on the ...
Cached Biology News:Mystery unraveled: How asbestos causes cancer 2Cheap, simple, noninvasive blood test may replace invasive diagnostic techniques in early pregnancy 2Cheap, simple, noninvasive blood test may replace invasive diagnostic techniques in early pregnancy 3Going out on a (redwood tree) limb 2Going out on a (redwood tree) limb 3